RASopathies. Part I: Genetics and therapeutic considerations
Authors:
Open Access
- 13 June 2025
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (6) , 1591-1602
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a ChildJAMA Dermatology, 2019
- Recent developments in neurofibromatoses and RASopathies: Management, diagnosis and current and future therapeutic avenuesAmerican Journal of Medical Genetics Part A, 2014
- Prevalence and clinical features of Costello syndrome and cardio‐facio‐cutaneous syndrome in Japan: Findings from a nationwide epidemiological surveyAmerican Journal of Medical Genetics Part A, 2012
- Lethal presentation of neurofibromatosis and Noonan syndromeAmerican Journal of Medical Genetics Part A, 2011
- Costello syndrome with severe cutis laxa and mosaic HRAS G12S mutationAmerican Journal of Medical Genetics Part A, 2010
- Male‐to‐male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicismAmerican Journal of Medical Genetics Part A, 2009
- Somatic mosaicism for an HRAS mutation causes Costello syndromeAmerican Journal of Medical Genetics Part A, 2006
- HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlationAmerican Journal of Medical Genetics Part A, 2005
- Different mutations in theNF1gene are associated with Neurofibromatosis–Noonan syndrome (NFNS)American Journal of Medical Genetics Part A, 2003
- Noonan phenotype associated with neurofibromatosisAmerican Journal of Medical Genetics, 1985